CPT1A and breast carcinoma: Thus, our data reveal that the CPT1 inhibitor etomoxir restores the sensitivity of endocrine-resistant breast cancer cells to fulvestrant and that combining etomoxir with fulvestrant synergistically reduces breast cancer cell growth.